Insider trades
David Lamond, Director of Quince Therapeutics QNCX, has filed 15 purchases and 0 sales on the open market. The latest trade was on 06/11.
David Lamond
Director
- Company
- Quince Therapeutics QNCX
- First filing
- 23/05/26
- Trades
- 21 trades
- Buys / sales
- 15 / 0
- 12-month net buying
- No record
- Last trade
- 06/11
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
QNCX | Open-market buy | 23/12/12–23/12/14 | 23/12/14 | 67,881 sh4 trades | $1.02avg. | $69,232.62 | No record |
QNCX | Open-market buy | 23/12/05–23/12/07 | 23/12/07 | 57,369 sh3 trades | $1.01avg. | $58,133.92 | +2.6% |
QNCX | Open-market buy | 23/11/29–23/12/01 | 23/12/01 | 43,134 sh3 trades | $0.94avg. | $40,545.96 | +2.0% |
QNCX | Open-market buy | 23/08/30–23/08/31 | 23/08/31 | 82,052 sh2 trades | $1.32avg. | $107,898.38 | +3.9% |
QNCX | Open-market buy | 23/08/15–23/08/17 | 23/08/17 | 250,000 sh3 trades | $1.30avg. | $325,736.58 | +13.5% |